BWAY Brainsway
- 6.290
- -0.270-4.12%
Brainsway News
BrainsWay Analyst Ratings
HC Wainwright & Co. : Maintaining the BrainsWay (BWAY.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $15.00.
HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $15
Buy Rating Affirmed for Brainsway Following Strong Financial Performance and Strategic Advancements
BrainsWay Analyst Ratings
Buy Rating and Raised Price Target for Brainsway Reflecting Strong Financial Growth and Expansion Potential
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), Brainsway (BWAY) and Wave Life Sciences (WVE)
Analysts Have Conflicting Sentiments on These Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP) and Brainsway (BWAY)
BrainsWay Analyst Ratings
Oppenheimer Adjusts Price Target on Brainsway to $6 From $5.50, Maintains Outperform Rating
Oppenheimer Keeps Their Buy Rating on Brainsway (BWAY)
BrainsWay Analyst Ratings
Promising Outcomes From Accelerated Deep TMS Treatment Study Bolsters Buy Rating for Brainsway
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $12 Price Target
BrainsWay Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM) and Brainsway (BWAY)
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $12 Price Target
BrainsWay Analyst Ratings
Analysts Offer Insights on Healthcare Companies: EFFECTOR Therapeutics (EFTR) and Brainsway (BWAY)
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $12 Price Target
Analysis
Price Target
No Data
